These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26451959)

  • 1. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
    Garziera M; Montico M; Bidoli E; Scalone S; Sorio R; Giorda G; Lucia E; Toffoli G
    PLoS One; 2015; 10(10):e0140351. PubMed ID: 26451959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel algorithm to improve specificity in ovarian cancer detection.
    Arjomandi A; Delanoy ML; Walker RP; Binder SR
    Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Fortner RT; Damms-Machado A; Kaaks R
    Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V; Salazar LG; Urban N; Drescher CW; Gray H; Swensen RE; McIntosh MW; Disis ML
    J Clin Oncol; 2006 Feb; 24(5):762-8. PubMed ID: 16391298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Gagetti O; Bevilacqua G; Genazzani AR
    Gynecol Oncol; 1999 Jan; 72(1):76-81. PubMed ID: 9889034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
    Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
    Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
    [No Abstract]   [Full Text] [Related]  

  • 12. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
    Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
    Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis.
    Sobhani N; Roviello G; D'Angelo A; Roudi R; Neeli PK; Generali D
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684792
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.
    Zhou Y; Bian B; Yuan X; Xie G; Ma Y; Shen L
    PLoS One; 2015; 10(6):e0130873. PubMed ID: 26098665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
    Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
    Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
    Yu L; Deng L; Li J; Zhang Y; Hu L
    Gynecol Oncol; 2013 Feb; 128(2):391-6. PubMed ID: 23142075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation.
    Green JA; Robertson LJ; Campbell IR; Jenkins J
    Cancer Detect Prev; 1995; 19(2):151-5. PubMed ID: 7750102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of anti-p53-autoantibodies in pancreatic disorders.
    Gansauge S; Gansauge F; Negri G; Galle P; Müller J; Nüssler AK; Poch B; Beger HG
    Int J Pancreatol; 1996 Jun; 19(3):171-8. PubMed ID: 8807362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.